The biosimilars market is not all about the United States, Europe, and Japan. Although these developed markets account for 80% of branded biologics sales, the rest-of-world segment includes many markets where treatment rates with branded biologics are currently low due to their high costs. Therefore, opportunity exists for biosimilars to expand the market and provide better access to biologic therapy. Regulators in more than 20 of the growth markets have adopted biosimilars guidelines and are eager to establish their own biosimilars industries. A wide range of companies are embarking on biosimilars development within their domestic markets and overseas. Understanding who the key competitors are in each region is critical to both biosimilar developers and branded biologic companies.
Markets covered: Global R&D pipeline of biosimilars and in-depth analysis of biosimilars competitive landscape in Europe, United States, Japan, India, South Korea, Brazil, and Mexico.
Primary research: Surveys with 560 specialist physicians across six different specialties in the United States and Europe. Surveys with an additional 60 U.S. managed care organization directors. Ten telephone interviews with key European payer advisors. Primary market research with key stakeholders to assess the following:
- Current opinions of biosimilars developed in emerging markets.
- How country of origin will affect biosimilar uptake.
- Perceptions of regulatory guidance.
Supportive primary market research with physicians in South Korea, Brazil, and Mexico to assess the following:
- Familiarity with biosimilars.
- Perception of similarity between biosimilars and their reference products.
Global Biosimilars Development Pipeline Deliverable: Includes more than 280 biosimilars development candidates across 14 drug classes and 43 different reference molecule targets.